{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:49:32Z","timestamp":1775245772811,"version":"3.50.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1097\/fpc.0000000000000290","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T15:26:15Z","timestamp":1497367575000},"page":"279-284","source":"Crossref","is-referenced-by-count":14,"title":["Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder"],"prefix":"10.1097","volume":"27","author":[{"given":"Qianqian","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingguang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210213","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1522-7154(1996)2:2<99::AID-ANXI7>3.0.CO;2-8","article-title":"Cardio-respiratory and other symptom clusters in panic disorder","volume":"2","author":"Bandelow","year":"1996","journal-title":"Anxiety"},{"key":"R3-1-20210213","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/da.22572","article-title":"Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys","volume":"33","author":"DeJonge","year":"2016","journal-title":"Depress Anxiety"},{"key":"R4-1-20210213","doi-asserted-by":"crossref","first-page":"28033","DOI":"10.1038\/srep28033","article-title":"Meta-analysis of the prevalence of anxiety disorders in mainland China from 2000 to 2015","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"key":"R5-1-20210213","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/da.20141","article-title":"Escitalopram in the treatmentof anxiety symptoms associated with depression","volume":"24","author":"Bandelow","year":"2007","journal-title":"Depress Anxiety"},{"key":"R6-1-20210213","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1185\/030079906X115513","article-title":"A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severe major depression","volume":"22","author":"Boulenger","year":"2006","journal-title":"Curr Opin Med Res"},{"key":"R7-1-20210213","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00004850-200505000-00002","article-title":"Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder","volume":"20","author":"Moore","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"R8-1-20210213","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.jcp.0000195383.96383.25","article-title":"New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram","volume":"26","author":"Rampello","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R9-1-20210213","first-page":"94","article-title":"Early symptom change prediction of remission in depression treatment","volume":"42","author":"Katz","year":"2009","journal-title":"Psychopharmacol Bull"},{"key":"R10-1-20210213","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2217\/pgs.09.168","article-title":"Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response","volume":"11","author":"Tsai","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R11-1-20210213","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/jcpt.12320","article-title":"The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder","volume":"40","author":"Uckun","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"R12-1-20210213","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R13-1-20210213","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2217\/pgs.12.24","article-title":"CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects","volume":"13","author":"Chan","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R14-1-20210213","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40262-014-0162-1","article-title":"Impact of cytochrome P450 2C19 polymorphisms on citalopram\/escitalopram exposure: a systematic review and meta-analysis","volume":"53","author":"Chang","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R15-1-20210213","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881111414451","article-title":"CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP","volume":"26","author":"Huezo-Diaz","year":"2012","journal-title":"J Psychopharmacol"},{"key":"R16-1-20210213","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-004-0766-8","article-title":"Impact of polymorphisms of cytochrome P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting","volume":"60","author":"Grasm\u00e4der","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-1-20210213","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/hup.2340","article-title":"Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression","volume":"28","author":"Ng","year":"2013","journal-title":"Hum Psychopharmacol"},{"key":"R18-1-20210213","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jad.2016.07.027","article-title":"Association of childhood trauma and panic symptom severity in panic disorder: exploring the mediating role of alexithymia","volume":"206","author":"Zou","year":"2016","journal-title":"J Affect Disord"},{"key":"R19-1-20210213","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin Pharmacol Therap"},{"key":"R20-1-20210213","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R21-1-20210213","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.clpt.6100291","article-title":"Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients","volume":"83","author":"Rudberg","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R22-1-20210213","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/jcph.530","article-title":"CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo controlled a tomoxetine maintenance of response clinical trial","volume":"55","author":"Fijal","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"R23-1-20210213","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11096-013-9783-y","article-title":"CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention","volume":"35","author":"Mejin","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"R24-1-20210213","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/jcpt.12254","article-title":"Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from northwestern China","volume":"40","author":"Lin","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"R25-1-20210213","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MCA.0000000000000092","article-title":"CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention","volume":"25","author":"Liu","year":"2014","journal-title":"Coron Artery Dis"},{"key":"R26-1-20210213","doi-asserted-by":"crossref","first-page":"e43412","DOI":"10.1371\/journal.pone.0043412","article-title":"Interaction between alcohol consumption and CYP 2C19 gene polymorphism in relation to oesophageal squamous cell carcinoma","volume":"7","author":"Shi","year":"2012","journal-title":"PLoS One"},{"key":"R27-1-20210213","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4238\/2011.December.5.9","article-title":"Interaction between CYP 2C19*3 polymorphism and smoking in relation to laryngeal carcinoma in the Chinese Han population","volume":"10","author":"Feng","year":"2011","journal-title":"Genet Mol Res"},{"key":"R28-1-20210213","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1046\/j.1365-2036.2001.01108.x","article-title":"Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH","volume":"15","author":"Shirai","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-1-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e328340bc5a","article-title":"CYP2C19 variation and citalopram response","volume":"21","author":"Mrazek","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R30-1-20210213","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/cap.2006.16.131","article-title":"The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression","volume":"16","author":"Findling","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R31-1-20210213","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol Psychiatry"},{"key":"R32-1-20210213","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FPC.0000000000000173","article-title":"Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder","volume":"25","author":"Bishop","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"R33-1-20210213","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/0269881113512041","article-title":"Genetic differences in cytochrome P450 enzymes and antidepressant treatment response","volume":"28","author":"Hodgson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"R34-1-20210213","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jad.2008.10.011","article-title":"Does early improvement triggered by antidepressants predict response\/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression","volume":"115","author":"Henkel","year":"2009","journal-title":"J Affect Disord"},{"key":"R35-1-20210213","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40263-014-0171-5","article-title":"Early switching strategies in antidepressant non-responders: current evidence and future research directions","volume":"28","author":"Kudlow","year":"2014","journal-title":"CNS Drugs"},{"key":"R36-1-20210213","first-page":"1102","article-title":"Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram","volume":"29","author":"Von Moltke","year":"2001","journal-title":"Drug MetabDispos"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:23:56Z","timestamp":1620951836000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201708000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000290","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}